Castrate resistant prostate cancer is an advanced stage of prostate cancer that does not respond to androgen deprivation therapy. Increasing prevalence of prostate cancer and rising demand for advanced treatment options are major factors contributing to growth of the castrate resistant prostate cancer market.
The Global Castrate Resistant Prostate Cancer Market Demand is estimated to be valued at US$ 12.82 billion in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period from 2024 to 2030.
Prostate cancer is one of the most commonly occurring cancers in men. According to the National Cancer Institute, there were around 268,490 new cases of prostate cancer in the United States in 2022. Androgen deprivation therapy is the standard treatment for advanced prostate cancer. However, in many cases the cancer becomes resistant to androgen deprivation over time and continues to progress, leading to castrate resistant prostate cancer (CRPC). Drugs for treating CRPC play a crucial role in improving survival and quality of life of patients. Some of the key advantages of CRPC drugs include improved therapeutic efficacy and reduced risks of cancer recurrence and death. With rising incidence of prostate cancer cases and limited treatment alternatives for late-stage CRPC, the demand for effective CRPC drugs is increasing significantly.
Key Takeaways
Key players operating in the castrate resistant prostate cancer market include Bayer AG, Johnson & Johnson, Amgen, Pfizer, AstraZeneca, Sanofi, and Astellas Pharma. Bayer’s Nubeqa and J&J’s Erleada are among the top-selling CRPC drugs.
North America dominates the global CRPC drugs market due to growing patient pool, favourable reimbursement policies, and high adoption of novel therapeutics. According to Prostate Cancer Foundation, around 268,000 new prostate cancer cases will be diagnosed in United States in 2022.
Key players are investing heavily in R&D to develop innovative treatment approaches for advanced prostate cancer. partnerships and acquisition activities are also on a rise to enhance product pipelines. In 2023, Darna BioSciences raised $80 million to advance pipeline of novel CRPC therapeutics.
Rising geriatric population worldwide presents significant growth opportunities. Asia Pacific region is anticipated to witness fastest growth during the forecast period supported by improving access toancer healthcare in China and India.
Market Drivers
Prevalence of prostate cancer is increasing rapidly worldwide driven by aging population and changing lifestyle factors. According to WHO, incidence rates of prostate cancer are highest in developed countries. Growing patient pool is the primary driver of CRPC therapeutics market.
Market Restraints
High cost of CRPC drugs limits their adoption in developing nations. For instance, average cost of CRPC treatment exceeds $120,000 per patient in the US. Existing therapies also have severe side effects such as fatigue, diarrhoea, & bone pain, reducing patient compliance. Stringent regulatory approval process also restrains market growth.
Segment Analysis
There are 3 main segments of the castrate resistant prostate cancer market - chemotherapy, hormonal therapy, and targeted therapy. The targeted therapy segment currently dominates the market owing to the better efficacy and lesser side effects offered by targeted drugs such as abiraterone, enzalutamide, and sotirilimab used in targeted therapy. Within targeted therapy, the immunotherapies sub-segment shows the most promise for future growth since immune checkpoint inhibitors have shown survival benefits and are being increasingly used in treatment protocols.
Global Analysis
North America has the largest share in the castrate resistant prostate cancer market currently due to high awareness levels, advanced healthcare infrastructure, favorable reimbursement policies, and presence of major market players in the region. It is expected to continue dominating the market during the forecast period. However, the Asia Pacific region is likely to grow at the fastest CAGR during this period owing to rising healthcare expenditure, growing geriatric population, increasing adoption of advanced treatment options, and healthcare reforms across many countries in the region.
Get more insights on this topic: Castrate Resistant Prostate Cancer Market
Comments
0 comment